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Background: Kynurenine aminotransferase 3 (KAT3) catalyzes the transamination of Kynurenine to ky-
nurenic acid, and is identical to cysteine conjugate beta-lyase 2 (CCBL2) and glutamine transaminase L
(GTL). GTL was previously puriﬁed from the rat liver and considered as a liver type glutamine transa-
minase. However, because of the substrate overlap and high sequence similarity of KAT3 and KAT1, it was
difﬁcult to assay the speciﬁc activity of each KAT and to study the enzyme localization in animals.
Methods: KAT3 transcript and protein levels as well as enzyme activity in the liver and kidney were
analyzed by regular reverse transcription-polymerase chain reaction (RT-PCR), real time RT-PCR, bio-
chemical activity assays combined with a speciﬁc inhibition assay, and western blotting using a puriﬁed
and a highly speciﬁc antibody, respectively.
Results: This study concerns the comparative biochemical characterization and localization of KAT 3 in
the mouse. The results showed that KAT3 was present in both liver and kidney of the mouse, but was
much more abundant in the kidney than in the liver. The mouse KAT3 is more efﬁcient in transamination
of glutamine with indo-3-pyruvate or oxaloacetate as amino group acceptor than the mouse KAT1.
Conclusions: Mouse KAT3 is a major glutamine transaminase in the kidney although it was named a liver
type transaminase.
General signiﬁcance: Our data highlights KAT3 as a key enzyme for studying the nephrotoxic mechanism
of some xenobiotics and the formation of chemopreventive compounds in the mouse kidney. This sug-
gests tissue localizations of KAT3/GTL/CCBL2 in other animals may be carefully checked.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Kynurenine aminotransferase (KAT) catalyzes the transamina-
tion of kynurenine to kynurenic acid (KYNA). KYNA is the only
known endogenous antagonist of the N-methyl-D-aspartate sub-
type of glutamate receptors [1–4]. It is also the antagonist of the
α7-nicotinic acetylcholine receptor [5–8]. Because of the pivotal
role KYNA plays, KATs have been paid a great attention for theirB.V. This is an open access article u
GTK, glutamine transaminase
minotransferase; KYNA, ky-
al Veterinary Medicine and
sity, Haikou, Hainan 570228,
n@foxmail.com (Q. Han).functions in the central nervous system (CNS) [9,10]. In addition to
the roles in CNS, KYNA is also involved in the control of the car-
diovascular function [11] and physiological blood pressure [12,13].
In humans, rats and mice, four KAT enzymes, KATs 1, 2, 3 and
4 were reported [9]. Among the four mammalian KATs, KAT1 and
KAT3 share similar genomic structure and high sequence identity
[14] and therefore likely have overlapped biological functions.
KAT1 is identical to glutamine transaminase K (GTK), a kidney type
transaminase and cysteine conjugate beta-lyase 1 (CCBL1). Re-
cently, it was demonstrated that KAT3 is not only identical to cy-
steine conjugate beta-lyase 2 (CCBL2), but also to glutamine
transaminase L (GTL), a liver type glutamine transaminase [15].
Based on the biochemical property of mouse KAT3, it efﬁciently
catalyzes the transamination reaction of glutamine, methionine,
phenylalanine and cysteine [16].
Although the involvement of KAT1 and KAT3 in brain KYNA
production has frequently been discussed [9], their speciﬁcnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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kidneys than in brains [14,17]. GTK is referred to as KAT1 in most
cases [18–20], but the fact is that glutamine is a much better
substrate of the enzyme than is kynurenine [20]. Moreover, glu-
tamine is one of the most abundant free amino acids in the body
and central to many of the pathways of intermediary metabolism
[21]. The concentration of glutamine in most tissues, including the
liver and kidney, is in the mM range [22,23], whereas the con-
centration of kynurenine in liver has been reported to be about
0.4 μM [24]. Therefore, glutamine transamination activity of GTK
and GTL may play a fundamental role in metabolism of glutamine.
Glutamine is metabolized by mechanisms of the glutaminase
and glutaminase II pathways. It is suggested that the glutaminase
II pathway is quantitatively important in humans [25]. Glutami-
nase II pathway consists of a glutamine transaminase coupled to
ω-amidase. Transamination of glutamine results in formation of
the corresponding α-ketoglutaramate which is hydrolyzed by ω-
amidase to α-ketoglutarate and ammonia [26]. This glutaminase II
pathway plays many roles in animals and humans. Glutamine
transaminases function as repair enzymes that salvage a number
of α-keto acids, and play roles in nitrogen and sulfur homeostasis,
1-carbon metabolism, and the formation of chemopreventive
metabolites of seleno-amino acids. The glutamine transaminases,
including GTK and GTL may contribute to the detoxiﬁcation of
halogenated alkenes and possibly other xenobiotic electrophiles,
many of which are environmental contaminants [25,27]. In addi-
tion, the “glutamine addiction” of many tumors suggests that the
glutamine transaminases may have a fundamental, inﬂuential role
in regulating cancer progression although the role of the gluta-
minase II pathway in cancer biology has been less studied. Con-
sidering the above facts and the importance of glutamine meta-
bolism, the mouse KAT3/GTL/CCLB2 may play more important
roles in kidney and liver than in the brain. In this paper, we
investigated its expressions, localizations and enzyme activity in
the liver and kidney, and assessed its potential roles regarding
transamination activity towards glutamine and others except
kynurenine.2. Methods
2.1. Expression and puriﬁcation of recombinant mouse KAT1 and
KAT3
Both recombinant mouse KAT1 and KAT3 were expressed and
puriﬁed as previously described [28]. Brieﬂy, ampliﬁed KAT1 and
KAT3 sequences were cloned into an Impact™-CN plasmid (New
England Biolabs) for expression of a fusion protein containing a
chitin-binding domain. Transformed Escherichia coli cells were
used to produce the recombinant proteins. The expressed proteins
were puriﬁed using afﬁnity puriﬁcation, DEAE-Sepharose, Mono-Q
and gel-ﬁltration chromatography. The puriﬁed recombinant KAT1
and KAT3 were concentrated to 10 mg mL1 protein in 10 mM
phosphate buffer (pH 7.5) containing 40 mM pyridoxal-5′-phos-
phate (PLP) and 10 mM b-mercaptoethanol using a Centricon YM-
50 concentrator (Millipore). Protein concentration was tested by a
protein assay kit from Bio-Rad (Hercules, CA) using bovine serum
albumin as a standard.
2.2. Glutamine transaminase and KAT activity assay
KAT activity assay was based on previously described methods
[28]. Brieﬂy, a reaction mixture of 100 μL, containing 5 mM L-ky-
nurenine, 2 mM glyoxylate or other α-keto acid (for co-substrate
test), 40 μM PLP, and 5 μg of recombinant protein, was prepared
using 100 mM potassium phosphate buffer (pH 7.5). The mixturewas incubated for 15 min at 38 °C, and the reaction stopped by
adding an equal volume of 0.8 M formic acid. The supernatant of
the reaction mixture, obtained by centrifugation at 15,000g for
10 min, was analyzed for the product, KYNA, by high-performance
liquid chromatography (HPLC) with ultraviolet detection at
330 nm.
A glutamine transaminase activity assay was developed here. A
reaction mixture of 100 ml consisted of 2 mg of puriﬁed KAT en-
zymes, 5 mM glutamine, 2 mM phenylpyruvate, and 40 mM PLP in
100 mM boric acid buffer, pH 9.0, in 15 min at 38 °C. The reaction
mixture was incubated for 15 min at 38 °C and the reaction was
stopped by adding an equal volume of 0.8 M formic acid into the
reaction mixture. The mixture was centrifuged for 10 min at
15,000g and supernatant (5 ml) was injected into an HPLC reverse-
phase column (1504.6 mm, Varian, Palo Alto, CA) for analysis.
The formation of transamination product, phenylalanine was
monitored by an on-line UV detector at a wavelength of 257 nm.
2.3. Co-substrate speciﬁcity of mouse KAT1 and KAT3
To determine the substrate speciﬁcity for α-keto acids, 16 α-
keto acids were individually tested for their ability to function as
an amino group acceptor for mouse KAT1 and KAT3. Each of the 16
α-keto acids were assayed at 2 mM in the presence of 5 mM ky-
nurenine in the 100 mL reaction mixture prepared in 100 mM
phosphate buffer, including 40 μM PLP. The rate of KYNA pro-
duction was determined as described in the KAT activity assay.
2.4. Glutamine activity assay for mouse tissue crude proteins
Three female and three male mice were sacriﬁced and their
livers and kidneys were immediately removed and transferred into
a protein extract buffer (50 mL of 50 mM Tris–acetate buffer con-
taining 40 mM PLP, 10 mM β-mercaptoethanol, 2 mM EDTA, and
1 mM PMSF at pH 8.0). The livers and kidneys were homogenized
in a pre-cooled homogenizer, separately. The mixture was cen-
trifuged at 20,000g, 4 °C, for 20 min. The supernatant was col-
lected, and dialyzed overnight at 4 °C against the protein extract
buffer with a 50 kDa molecular weight cutoff membrane. The
dialyzed crude protein extracts were used for enzyme activity
assay, inhibition assay and western blotting. The crude protein
concentration was determined by a protein assay kit from Bio-Rad
(Hercules, CA) using bovine serum albumin as a standard. A crude
extract sample containing 20 μg protein was used in 100 μl of the
same typical reaction mixture as was used in the recombinant
protein activity assay. The mixture was incubated at 38 °C for 2 h.
2.5. Western blot analysis
2.5.1. Puriﬁcation of anti mouse KAT3 antibody
In order to get speciﬁc anti-mouse KAT3 antibody without
cross-reacting with mouse KAT1, the very similar protein to KAT3,
we puriﬁed KAT3 antibodies and veriﬁed the speciﬁcity by wes-
tern-blotting. Brieﬂy, the anti mouse KAT3 rabbit polyclonal anti-
body was obtained from Santa Cruz (Cat#SC-67378). The anti-
serum was diluted into 2 volumes with ice cooled sterile saline,
and passed through 0.45 μm ﬁlter. Saturated ammonium sulfate
solution was added into the sample up to 50% saturation, and
stored at 4 °C for 4 h. The mixture was centrifuged at 15 kg for
10 min at 4 °C, and the precipitated protein was dissolved in 1
volume of ice-cooled saline. 1/2 volume saturated ammonium
sulfate was added in the solution up to 33% saturation, and kept at
4 °C for at least 4 h. After centrifugation, the precipitated protein
(IgG) was dissolved in PBS, and subjected to further afﬁnity pur-
iﬁcation. The antibody was ﬁrst absorbed by the recombinant
mouse KAT1 protein fused with a chitin-binding domain and ﬁxed
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with PBS while all ﬂowed through protein that was not bound to
KAT1 protein was collected and concentrated using a Millipore
protein concentrator with 10 kDa molecular weight cutoff. The
speciﬁcity of the concentrated protein was tested by western blot
analysis using horseradish peroxidase catalyzing color change.
2.5.2. Western blotting
Twenty μg crude liver or kidney protein sample was boiled for
5 min in Laemmli sample buffer and then separated by SDS-PAGE
at 12% polyacrylamide using a Hoefer SE 260 mini-vertical gel
electrophoresis apparatus at 180 V. Separated proteins in the
polyacrylamide gel were transferred onto a PVDF membrane (GE
Healthcare) in CAPS buffer (10 mM CAPS, pH11.0) at 400 mA using
a Hoefer TE 22 transfer apparatus. The membrane was blocked
with 5% BSA in 1 PBST (PBS with Tween 20) and incubated with
the puriﬁed primary antibody (1:500 diluted in 1 PBST with 1%
BSA) overnight at 4 °C. The membrane was washed three times for
10 min each in PBST, and incubated with goat anti-rabbit IgG
(whole molecule) conjugated with HRP (1:10,000 in 1 PBST with
0.5% BSA) (Sigma-Aldrich) for 90 min. After extensive wash, the
membrane was incubated in 2.0 mM 3,3′-diaminobenzidine solu-
tion prepared in PBS for 5 min. The image of immunoblot was
digitalized with the Alphaimager HP system (Alpha Innotech) and
saved as TIF format.
2.6. RT-PCR and qRT-PCR analyses
2.6.1. RT-PCR
The kidney or liver tissues from three females and three males
were grinded to powder in liquid nitrogen. Approximately 50 mg
of kidney or liver power was used to extract total RNA using a
mirVana miRNA Isolation Kit (Ambion, Inc.) according to the
manufacturer's instructions. Total RNA was treated with RNase
free DNAase. After heat-inactivation, total RNA was reverse tran-
scribed to the ﬁrst-strand cDNA using SuperScript™ III First-Strand
Synthesis System (Invitrogen) with oligo (dT) 18 primer. The
mRNA transcripts of mouse KAT1 and KAT3 were analyzed using
RT-PCR. A speciﬁc primer pair for KAT1 (Forward: 5′-GAGCTG-
GAGCTGGTGGCTGC-3′ and Reverse: 5′-GCGCTGCCGATGGT-
CAGTGT-3′) that ampliﬁes a 152 bp product and speciﬁc primer
pairs for KAT3 (Forward: 5′-GCTGACCTTTGCGTCAAGCACG-3′ and
Reverse: 5′-GGGCCAATGCTCCAGCCGAG-3′) that ampliﬁes a 188 bp
DNA fragment were designed and used for PCR ampliﬁcation. A
mouse β-actin gene was used as a control (Forward primer: 5′-
GCGGACTGTTACTGAGCTGCGT-3′ and Reverse primer: 5′-
TGCTGTCGCCTTCACCGTTCC-3′. Product length¼217 bp). The PCR
reaction consisted of 2 min at 94 °C, 30 cycles (each cycle: 94 °C for
30 s, 60 °C for 30 s, 72 °C for 1 min), and a ﬁnal extension at 72 °C
for 10 min. All ﬁnal products were analyzed by 1% agarose gel
electrophoresis. The image was digitalized with the Alphaimager
HP system (Alpha Innotech).
2.6.2. qRT-PCR analyses
To conﬁrm the RT-PCR results, six different female (3) and male
(3) mice were chosen for qRT-PCR experiment. The total RNA extrac-
tion and the ﬁrst-strand cDNA synthesis were same as described
above. The qRT-PCR ampliﬁcations were performed with ROCHE
LightCycler 96 using a FastStart Essential DNA Green Master (Roche).
Each sample was ampliﬁed in triplicate. The primer sequences were:
Ccbl1/kat1 sense 5′-GGAGATGGACCCACTCAAGAAT-3′ and antisense 5′-
GCCTGAAAGGCTGTGAACAAG-3′; Ccbl2/kat3 sense 5′-AACCCCGGCGA-
CACCTA-3′, and antisense 5′- TGATCGTTCTCCTGGTTCCAA-3′; Gapdh
sense 5′-TGCACCACCAACTGCTTAGC-3′, and antisense 5′- CAGTCTTCT-
GAGTGGCAGTGATG-3′, which are different from the above RT-PCR
primers. The qRT-PCR ampliﬁcation conditions were: denaturation at94 °C for 2 min followed by 30–35 cycles of 94 °C for 10 s and 72 °C for
30 s. Fluorescence values were recorded at 72 °C. Melting curve ana-
lysis was performed to conﬁrm speciﬁc ampliﬁcation. Relative ex-
pression levels of target genes were calculated by the 2ΔΔCt method
[29].
2.7. Statistical analysis
The results of enzyme activities and relative transcript levels
were analyzed by Student's t-test.3. Results
3.1. Comparison of co-substrate speciﬁcities of mouse KAT1 and
KAT3
For comparison, two KATs were tested for KAT activity towards
16 different α-ketoacids. They share many α-ketoacids as co-
substrates, showing relatively high activities with glyoxylate, α-
Ketoisocaproic acid, phenylpyruvate, α-ketovalerate, mercapto-
pyruvate and αKMB. With respect to the speciﬁcities of these co-
substrates, both enzymes behaved similarly. However, differences
between mouse KAT1 and KAT3 became evident with α-ketoiso-
leucine, oxaloacetate or indo-3-pyruvate. Mouse KAT1 showed
high activity with α-ketoisoleucine, and little activity with indo-3-
pyruvate and oxaloacetate, while mouse KAT3 displayed high ac-
tivity with indo-3-pyruvate and oxaloacetate, and little activity
with α-ketoisoleucine (Fig. 1). The co-substrate proﬁle of mouse
KAT1 was essentially the same as human KAT1 except the mouse
enzyme showed a high activity with α-ketoisoleucine, while the
activity of human KAT1 was undetectable under the same reaction
conditions [20].
3.2. Glutamine transaminase activity assay using phenylpyruvate as
a co-substrate
A glutamine transaminase activity assay using HPLC UV–vis
detection was developed here. The enzyme reaction mixture
(100 μl) includes 5 mM glutamine, 2 mM phenylpyruvate and 2 μg
recombinant mouse KAT3 or KAT1, 100 mM boric acid buffer, pH
9.0. The mixture was incubated at 38 °C for 15 min. The reaction
was stopped by adding an equal volume of 0.8 M formic acid. The
mixture was centrifuged and the supernatant was injected into an
HPLC column (1504.6 mm, Varian, Palo Alto, CA) for analysis.
The mobile phase consists of 10 mM potassium phosphate
(monobasic) buffer containing 10% (v/v) acetonitrile for the ana-
lysis of phenylalanine in the reaction mixtures. The formation of
transamination product, phenylalanine was monitored by an on-
line UV detector at a wavelength of 257 nm. The activity assays
showed both mouse KAT1 and KAT3 had glutamine transaminase
activities using phenylpyruvate as a co-substrate. Fig. 2 showed
chromatograms of the assay using mouse KAT3 as an example. In
the ﬁgure, phenylpyruvate was consumed completely by the en-
zyme to produce phenylalanine. Table 1 showed enzyme kinetic
parameters towards glutamine and phenylalanine.
3.3. Inhibition of glutamine transaminase activities of mouse KAT1
and KAT3
In order to ﬁnd the biochemical differences of KAT1 and KAT3,
inhibition of two enzymes were investigated. Based on the pre-
vious reports regarding their biochemical characteristics [16,28],
the inhibitor, methionine was tested for the inhibition of gluta-
mine transaminations catalyzed by mouse KAT1 and KAT3. When
the enzyme activity was assayed in a typical reaction mixture
Fig. 1. Transamination activity of two KATs towards different α-ketoacids. Puriﬁed recombinant mouse KAT1 and KAT3 were incubated with each of 16 α-ketoacids at 2 mM
in the presence of 5 mM kynurenine in a reaction mixture including 40 μM PLP and 100 mM phosphate, pH 7.5. The activity was quantiﬁed by the amount of KYNA produced
in the reaction mixture. (A) mouse KAT1; (B) mouse KAT3.
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KAT1) in the presence of 5 mM inhibitor, methionine, no notice-
able inhibitory effect on mouse KAT1-catalyzed glutamine trans-
amination was observed, however methionine greatly decreased
the rate of glutamine transamination (57%) of mouse KAT3 (Fig. 3).
The decrease in the rate of KAT3-catalyzed reaction in the pre-
sence of the inhibitors is apparently due to competitive inhibition
of mouse KAT3.
3.4. KAT and glutamine transaminase activities of mouse kidney and
liver crude proteins
At the identical conditions as used above in the co-substrate
speciﬁcity and inhibition studies of mouse KAT1 and KAT3 en-
zymes, the liver and kidney crude proteins showed KAT and glu-
tamine transaminase activities (Fig. 4). In particular, the crude liver
proteins showed higher KAT and glutamine transaminase activities
than did the kidney crude proteins. By estimating KAT1 and KAT3
contribution to the detected enzyme activities in the liver and
kidney, we did speciﬁc inhibition tests for the crude proteins. The
results showed that enzyme activity of the kidney crude proteins
was inhibited by methionine, and the crude proteins from mouse
liver were not inhibited signiﬁcantly by the inhibitor (Fig. 4). This
result indicated that mouse KAT3/GTL/CCBL2 is mainly present in
kidney in mouse, not in liver.
3.5. Expressions of kat3 and kat1 genes in the mouse liver and
kidney
The expressions of kat1 and kat3 genes in the mouse liver and
kidney were analyzed in six mice (three males and three females)
by RT-PCR (Fig. 5A) and qRT-PCR (Fig. 5B). kat1 and kat3 showed
different and measureable expression levels, and both genes were
expressed in both liver and kidney of the mouse. However, kat1
was expressed in a higher level in the liver than in the kidney,
while kat3 was expressed in a higher level in the kidney than in
the liver.
3.6. Western blot analysis
In order to reveal KAT3 localization in the mouse kidney and
liver, we did western-blotting using the puriﬁed anti KAT3 anti-
body, which was puriﬁed from the anti-serum produced in a
rabbit. The antibody had no cross-reaction with mouse KAT1 by
western-blotting (Fig. 5C). The results showed that KAT3 proteinwas found both in the mouse liver and kidney, but more abundant
in the kidney (Fig. 5D).4. Discussion
It has been reported that glutamine transaminase has at least
two forms: K-form (GTK) puriﬁed from kidney, and L-form (GTL)
puriﬁed from liver in rats [30–32]. GTK has been cloned and linked
to KAT1 [33–35], and GTL protein has been linked to KAT3 [15].
Thus, it is considered that GTK is a main glutamine transaminase
in the rat kidney tissue; and GTL is a main glutamine transaminase
in the rat liver [17]. The annotation of mouse homologs of gluta-
mine transaminases was based on the sequence identity, which
may not provide information of tissue localization of the enzymes.
In this study, we provided evidence that the mouse KAT3/GTL was
found both in the liver and kidney of the mouse, but the mouse
KAT3/GTL was more abundant in the kidney than in the liver,
which contrasts to the rat homolog (rat KAT3/GTL) that is abun-
dant in the liver. This conclusion is supported by multiple ex-
perimental results. First of all, both independent RT-PCR and qRT-
PCR experiments showed that relative mRNA levels of kat3 gene
were higher in the kidney than in the liver of the mouse compared
with those of house keeping genes. Secondly, previous studies
found that the mouse KAT3 was inhibited by equimolar con-
centration methionine, while human KAT1 and mouse KAT1 were
not signiﬁcantly inhibited by equimolar concentration methionine
[9,16,28]. Therefore, inhibition levels of methionine could be used
to distinguish natural enzyme activity of the mouse KAT1/GTK and
KAT3/GTL from tissues. Glutamine transaminase activity of the
mouse kidney crude protein was signiﬁcantly inhibited by me-
thionine, while the enzyme activity from the mouse liver crude
protein was not signiﬁcantly inhibited, suggesting that KAT3/GTL
is more abundant in the mouse kidney than in the liver. Finally,
western blotting using puriﬁed anti-mouse KAT3/GTL antibody
further demonstrated the protein level of KAT3/GTL is also more
abundant in the kidney than in the liver. Note that GTL means liver
type glutamine transaminase, which is not proper for naming the
mouse homologue, but GTL is retained for the mouse homologue,
mouse KAT3/GTL/CCBL2, for biochemical and gene structure si-
milarities in this report.
The tissue localization difference may raise a question as to
why the mouse KAT3/GTL tissue localization is different from the
rat KAT3/GTL. To answer why mouse GTL is abundant in the kidney
instead of the liver, we may look over any differences in
Fig. 2. HPLC UV–vis detection of glutamine transaminase activity. The reaction mixtures, standards and buffers were mixed with an equal volume of 0.8 M formic acid before
being injected into an HPLC reverse-phase column (1504.6 mm, Varian, Palo Alto, CA) for analysis. The mobile phase consists of 10 mM potassium phosphate (monobasic)
buffer containing 10% (v/v) acetonitrile for the analysis of phenylalanine in the reaction mixtures. The formation of transamination product, phenylalanine was monitored by
an in-line UV detector at a wavelength of 257 nm. A, B, C, and D illustrate chromatograms of boric acid buffer, 1 mM phenylpyruvate standard, 1 mM phenylalanine standard,
and the reaction mixture without incubation, respectively. Chromatogram E illustrates the product, phenylalanine (arrowed) formed in 100 μl reaction mixture including
5 mM glutamine, 2 mM phenylpyruvate and 2 μg recombinant mouse KAT3, 100 mM boric acid buffer, pH 9.0, in 15 min at 38 °C. The reaction was stopped by adding an
equal volume of 0.8 M formic acid.
Table 1
Kinetic parameters of mKAT 1 & 3 towards glutamine and phenylpyruvate.
Km (mM) kcat (min1) kcat/Km
(min1 mM1)
mKAT I/GTK Glutamine 2.370.4 410.5723.7 178.5
Phenylpyruvate 0.870.3 300.2716.3 375.3
mKAT3/GTL Glutamine 0.770.3 160.0715.0 228.6
Phenylpyruvate 0.670.2 190.0728.3 316.7
The activities were measured as described in the Method section. The Km and kcat
were derived by using varying concentrations (0.2–20 mM) of individual substrate
in the presence of 20 mM of glutamine or 5 mM phenylpyruvate. The parameters
were calculated by ﬁtting the Michaelis–Menten equation to the experimental data
using the enzyme kinetics module. Results are means7SE.
C. Yang et al. / Biochemistry and Biophysics Reports 8 (2016) 234–241238biochemical property and substrate availability between the
mouse and rat enzymes. Both selenomethionine and Se-methy-
selenocysteine are substrates of rat KAT1/GTK, human KAT1/GTK
and mouse KAT3/GTL in the presence of α-keto-γ-methiolbutyrate
as amine acceptor [15,25,36]. Selenomethionine is a relatively
good aminotransferase substrate of recombinant mouse KAT3/GTL,
suggesting that it selectively metabolizes selenomethionine to α-
keto-γ-methylselenobutyrate. However, it seems that KAT3/GTL is
more efﬁcient in transamination of both selenomethionine and Se-
methyselenocysteine than is KAT1/GTK. Here, we reported that
this enzyme was largely present in the kidney of the mouse,
suggesting that dietary selenomethionine and Se-methyseleno-
cysteine can be converted to the corresponding α-keto acids, α-
Fig. 3. Inhibition of glutamine transaminase activity of mouse recombinant KAT1 and KAT3 by methionine. The reaction mixture consisted of 5 mM glutamine, 2 mM
phenylpyruvate, 40 μM PLP, 2 μg recombinant protein, KAT1 or KAT3 in 100 mL 100 mM boric acid buffer, pH 9.0. The mixture was incubated at 38 °C for 15 min and the
reaction was stopped by adding an equal volume of 0.8 M formic acid. Measurement of phenylalanine product was performed by HPLC with UV detection at a wavelength of
257 nm. Panel B shows methionine signiﬁcantly inhibited KAT3 activity.
C. Yang et al. / Biochemistry and Biophysics Reports 8 (2016) 234–241 239keto-γ-methylselenobutyrate and β-methylselenopyruvate, re-
spectively in the mouse kidney. Selenium in the kidney tissues of
swine was greater than in the liver when it was provided as se-
lenomethionine [37]. The greatest concentrations were achieved
in the kidneys and adrenals in rats when given selenomethionine
[38]. In pigs, selenium concentration was generally the highest in
the kidney after administration of selenomethionine [39]. How-
ever, in the mouse, the liver absorbed the injected selenomethio-
nine more efﬁciently than did any other tissues, showing the
highest selenium concentrations [40]. Regarding the fact that se-
lenomethionine is a relatively good substrate of the mouse KAT3/
GTL, and possibly rat and human KAT3/GTL enzymes, the differ-
ences of tissue preference of selenomethionine between different
animals (higher concentration in the kidneys of the pig and rat,
higher concentration in the liver of the mouse) may explain the
different tissue localization of KAT3/GTL between mice and theFig. 4. Inhibition of glutamine transaminase activity of mouse liver and kidney crude p
2 mM phenylpyruvate, 40 μM PLP, 20 μl crude liver protein extract or kidney protein ex
38 °C for 2 h and the reaction was stopped by adding an equal volume of 0.8 M formic a
wavelength of 257 nm. Panel B shows methionine signiﬁcantly inhibited KAT activity inothers (rats and pigs), although the mechanism is not yet under-
stood. The kidney plays a major role in the interorgan metabolism
of glutamine [41]. As reviewed in the introduction, glutamine
transaminases play a role in acid-base homeostasis for producing
urinary ammonia production in the kidney. The excretion of am-
monia in the urine facilitates the elimination of strong metabolic
acids, such as sulfuric acid that arises during the catabolism of
methionine and cysteine [41,42]. Thus, the mouse KAT3/GTL is a
key glutamine transaminase in mice for the acid-base homeostasis
in the kidney.
In addition, α-Keto-γ-methylselenobutyrate and β-methylse-
lenopyruvate are potent inhibitors of histone deacetylases and
therefore may be chemoprotective [43,44]. Understanding the
extent of in situ conversion of seleno amino acid to α-keto-γ-
methylselenobutyrate and β-methylselenopyruvate by tissue spe-
ciﬁc glutamine transaminases (GTL or GTK) may be practical inrotein extracts by methionine. The reaction mixture consisted of 5 mM glutamine,
tract in 100 mL of 100 mM boric acid buffer, pH 9.0. The mixture was incubated at
cid. Measurement of phenylalanine was performed by HPLC with UV detection at a
the kidney.
Fig. 5. mRNA and protein levels of KATs in the mouse liver and kidney. The mRNA transcripts of mouse kat1 and kat3 in the liver and kidney were analyzed using both RT-
PCR and qRT-PCR. All ﬁnal products in RT-PCR experiments were analyzed by 1% agarose gel electrophoresis (A). Relative expression levels of kat1 and kat3 genes were
shown as percentages of gapdh gene expression in qRT-PCR tests (B). The speciﬁcity of the puriﬁed mouse KAT3 antibody was tested by Western blotting. Both recombinant
mouse KAT1 and KAT3 proteins were run in a SDS-PAGE, transferred to a PVDF membrane and immuno-stained with the puriﬁed mouse KAT3 antibody. The antibody
recognized the recombinant mouse KAT3 protein very well, without cross-reaction with recombinant mouse KAT1 (C). Using the puriﬁed mouse KAT3 antibody, KAT3
protein was detected both in liver and kidney, but a more intensive band was seen in the kidney (D).
C. Yang et al. / Biochemistry and Biophysics Reports 8 (2016) 234–241240interpreting treatment results of cancers in different tissues. Based
on what we reported about the mouse GTL localization, a further
study may be needed to conﬁrm the tissue localization of human
GTK and GTL in order to understand the treatment results of
cancers using seleno amino acids.
It was suggested that the glutaminase II pathway is quantita-
tively important in humans [25]. However, there is no evidence
showing the same phenomenon in the mouse. Here we provided
indirect evidence for that the glutaminase II pathway is more
important than the glutaminase pathway in metabolizing gluta-
mine in the mouse kidney based on the enzymes biochemical
parameter comparison. Km for glutamine of the rat glutaminase (a
key enzyme in glutaminase pathway) is 2.6 mM [45] and Km for
glutamine of the human kidney type glutaminase isozyme (GLS2)
is 4 mM. The Km value (0.7 mM) for glutamine of the mouse KAT3/
GTL, we reported here, was much smaller than Km values of both
rat glutaminase and human GLS2 (both for glutaminase pathway),
which suggests mouse KAT3/GTL will likely catalyze glutamine
more than did the others. If the mouse glutaminase and human
GLS2 behave the same as rat or human homologues, the reaction
may favor the glutaminase II pathway instead of the glutaminase
pathway. However, not having the enzyme kinetic parameters of
the mouse glutaminase and GLS2, we may not make a deﬁnite
conclusion for the major role the glutaminase II pathway plays in
the mouse kidney.
It has been established that KAT1 and KAT3 are multifunctional
aminotransferases. Kinetic analysis of the enzymes towards dif-
ferent amino acids showed that the enzyme is efﬁcient in cata-
lyzing the transamination of glutamine, phenylalanine, leucine,
kynurenine, tryptophan, methionine, tyrosine, histidine, cysteine
and aminobutyrate. The large spectrum of amino acid substrates of
KAT1 and KAT3 supports the proposed role of the enzyme in
sparing the essential amino acids methionine, histidine, phenyla-
lanine and tyrosine [46] and provides a mechanism to maintain a
continual equilibrium among the amino acids [47]. These enzymes
therefore appear to play a role in the homeostatic metabolic me-
chanism for the preservation of amino acid balance in which
glutamine, a dietary non-essential amino acid, functions to
maintain the tissue levels of amino acids and to prevent loss of
essential amino acid carbon chains [31,32]. Apparently, KAT3/GTL
is a major aminotransferase in playing such an important role in
the mouse kidney.Acknowledgments
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